[{"address1": "75 State Street", "address2": "Suite 1400", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "617 349 1971", "fax": "617 273 2637", "website": "https://www.astriatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Ms. Jill C. Milne Ph.D.", "age": 56, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 938776, "exercisedValue": 0, "unexercisedValue": 104569}, {"maxAge": 1, "name": "Mr. Noah C. Clauser CPA", "age": 50, "title": "CFO & Treasurer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 621406, "exercisedValue": 0, "unexercisedValue": 29493}, {"maxAge": 1, "name": "Dr. Christopher J. Morabito M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 661565, "exercisedValue": 0, "unexercisedValue": 134939}, {"maxAge": 1, "name": "Mr. Benjamin S. Harshbarger J.D.", "age": 55, "title": "Chief Legal Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 621908, "exercisedValue": 0, "unexercisedValue": 24123}, {"maxAge": 1, "name": "Ms. Keri  McGrail", "title": "Chief Human Resources Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea L. Matthews", "age": 41, "title": "Chief Business Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew A. Komjathy", "age": 60, "title": "Chief Commercial Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Ruesch", "title": "Senior Vice President of Pharmaceutical Sciences & Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rafif  Dagher", "title": "Senior VP and Head of Discovery, Nonclinical Development & Translational Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.45, "open": 7.43, "dayLow": 7.03, "dayHigh": 7.49, "regularMarketPreviousClose": 7.45, "regularMarketOpen": 7.43, "regularMarketDayLow": 7.03, "regularMarketDayHigh": 7.49, "forwardPE": -3.8432434, "volume": 235940, "regularMarketVolume": 235940, "averageVolume": 324033, "averageVolume10days": 268510, "averageDailyVolume10Day": 268510, "bid": 5.33, "ask": 9.08, "bidSize": 200, "askSize": 200, "marketCap": 401247168, "fiftyTwoWeekLow": 7.03, "fiftyTwoWeekHigh": 16.9, "fiftyDayAverage": 8.826, "twoHundredDayAverage": 10.114025, "currency": "USD", "enterpriseValue": 187441408, "floatShares": 32040050, "sharesOutstanding": 56434200, "sharesShort": 3094988, "sharesShortPriorMonth": 2684828, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.0548, "heldPercentInsiders": 0.0047400002, "heldPercentInstitutions": 1.05337, "shortRatio": 8.44, "shortPercentOfFloat": 0.056900002, "impliedSharesOutstanding": 58315400, "bookValue": 4.26, "priceToBook": 1.669014, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -100044000, "trailingEps": -2.18, "forwardEps": -1.77, "lastSplitFactor": "1:6", "lastSplitDate": 1629417600, "52WeekChange": -0.50333333, "SandP52WeekChange": 0.21027291, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ATXS", "underlyingSymbol": "ATXS", "shortName": "Astria Therapeutics, Inc.", "longName": "Astria Therapeutics, Inc.", "firstTradeDateEpochUtc": 1435239000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ed2b1d02-5c3d-3175-8863-7d0984fc667c", "messageBoardId": "finmb_100802824", "gmtOffSetMilliseconds": -18000000, "currentPrice": 7.11, "targetHighPrice": 35.0, "targetLowPrice": 16.0, "targetMeanPrice": 26.5, "targetMedianPrice": 26.5, "recommendationMean": 1.25, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 344283008, "totalCashPerShare": 5.954, "totalDebt": 5638000, "quickRatio": 21.895, "currentRatio": 22.377, "debtToEquity": 1.65, "returnOnAssets": -0.22719999, "returnOnEquity": -0.3803, "freeCashflow": -56598376, "operatingCashflow": -94088000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]